Cyclopharm (ASX:CYC) received an additional installation purchase order from a US Department of Veterans Affairs hospital for its Technegas product after its deployment under the Federal Supply
Schedule, according to a Tuesday Australian bourse filing.
Technegas is a structured ultra-fine dispersion of radioactive labelled carbon, which allows for views and tomography imaging under a gamma or single photon emission computed tomography camera.
Its sales receipts in the US exceeded $1 million since commercial sales began last year. Its US installed base as of March 31 reached 27 technegas systems, from 17 systems as of Dec. 31, 2024.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。